- Previous Close
0.4200 - Open
0.4248 - Bid 0.4340 x 301500
- Ask 0.4349 x --
- Day's Range
0.4105 - 0.4495 - 52 Week Range
0.4000 - 1.0900 - Volume
951,209 - Avg. Volume
1,655,507 - Market Cap (intraday)
523.1M - Beta (5Y Monthly) -0.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
www.nwbio.comRecent News: NWBO
Performance Overview: NWBO
Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NWBO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NWBO
Valuation Measures
Market Cap
523.10M
Enterprise Value
569.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
371.05
Price/Book (mrq)
--
Enterprise Value/Revenue
426.42
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-118.59%
Return on Equity (ttm)
--
Revenue (ttm)
1.34M
Net Income Avi to Common (ttm)
-72.21M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
2.48M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-38.43M